Smallpox vaccine - Acambis

Drug Profile

Smallpox vaccine - Acambis

Alternative Names: ACAM 3000 MVA; MVA 3000; MVA smallpox vaccine - Acambis

Latest Information Update: 24 Apr 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acambis
  • Developer Baxter Healthcare Corporation
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Smallpox

Most Recent Events

  • 15 Mar 2007 Discontinued - Phase-I for Smallpox in United Kingdom (Injection)
  • 15 Mar 2007 Discontinued - Phase-II for Smallpox in USA (Injection)
  • 31 Jul 2006 Final results from a phase II clinical trial in Smallpox Prevention have been added to the adverse events and Viral Infection immunogenicity sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top